- Thousands gather for candlelight vigil in Charlottesville
- Save the only Mangrove Forest Sundarbans a World Heritage Site
- Philippines records its bloodiest day EVER in war on drugs
- Obama makes history on Twitter
- Independence Day: Experience true sense of freedom at these destinations
- Bangladesh President, PM pay homage to Sheikh Mujibur Rahman on 42nd death anniversary
- Israeli Diamond magnate Steinmetz arrested in bribery case
- Flag-hoisting in Islamabad marks Pakistan's 70th Independence Day
- Hezbollah says Syrian government will stay on
- White nationalists march in Virginia, chant Nazi slogans
- Charlottesville and Trump: Hatred and violence grips America
- Israel-made fence systems, QRT troops at Pak, Bangladesh borders
Medigene Starts Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia AML
Organization : Medigene.
Website : www.medigene.com
Contact person : Anja Clausnitzer.
Email Address : email@example.com.
Medigene Starts Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML)
Martinsried/Munich, 24 March 2015. Biotechnology company Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the company’s phase I/II clinical trial with its dendritic cell (DC) vaccine for the treatment of acute myeloid leukaemia (AML) has started. Oslo University Hospital, Norway, the main trial centre, has begun to identify potentially eligible patients for enrollment. The study enables Medigene to evaluate its personalised DC vaccines in its first company-sponsored trial and generate further clinical feasibility and safety data of active immunotherapy, complementing ongoing academic clinical phase I/II and phase II studies.
Study design: Medigene’s phase I/II multi-centre, open-label trial will include 20 AML patients after completion of standard chemotherapy to reduce the risk of recurrence of leukaemia by using Medigene’s DC vaccines. Patients will be vaccinated for 50 weeks, with a follow-up period of one year or until progression. The primary objective is to prove feasibility and safety of active immunotherapy with Medigene’s DCs. Secondary objectives are induction of immune responses, control of minimal residual disease (MRD) and clinical response/time to progression (TTP).
Prof. Dolores J. Schendel, Chief Scientific Officer of Medigene AG, comments: “We are proud that the first company-sponsored clinical trial with Medigene’s new immunotherapy programs has started. The initiation of this trial is testament to the hard work by Medigene associates with our clinical partners in Oslo over the past years to develop this individualized DC vaccine approach for patients without further treatment options.”
Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy, Oslo University Hospital: ”Our success in developing a production process for these precision vaccines combined with initial clinical data from our ongoing investigator-initiated clinical trials with Medigene’s DC vaccine approach encourage us to further evaluate these promising new generation dendritic cells to efficiently activate T cell responses for the treatment of cancer.”
About Medigene’s DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies (formerly Trianta Immunotherapies): DC vaccines, TCR-based adoptive T cell therapy (TCRs) and T cell-specific monoclonal antibodies (TABs).
The DC vaccines are currently being evaluated in two ongoing clinical investigator-initiated trials: a clinical phase I/II trial in acute myeloid leukaemia (AML) at the Ludwig-Maximilian University Hospital Großhadern, Munich, and a clinical phase II trial in prostate cancer at the Oslo University Hospital. Moreover, a compassionate use programme1 is being conducted at the Department of Cellular Therapy at the Oslo University Hospital. Medigene concentrates on the further development of DC vaccines in hematological malignancies.
Data on patients with solid tumours who have received DC vaccines based on Medigene’s approach will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place from April 18-22 2015 in Philadelphia, USA (see Medigene’s press release from 19 March 2015).
Medigene’s dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce antigen-specific T cells to proliferate and mature. This way T cells can recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to become active and attack tumour cells. Scientists of Medigene Immunotherapies have developed new, fast and efficient methods for preparing autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells. The dendritic cells can be loaded with various tumour antigens to treat different types of cancer and are designed for treatment of minimal residual disease or use in combination therapies.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on hematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licenced to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.
Contact Medigene Julia Hofmann, Anja Clausnitzer Tel.: +49 - 89 - 20 00 33 - 33 01
Mumbai (Maharashtra) [India], July 31 (ANI): Falcons TTC emerged champions of the inaugural read more ..
Barcelona forward Neymar has now told Paris Saint-Germain he wants to move to the Parc des read more ..
Friday, August 18, 2017
New Delhi [India], May 22 (ANI-NewsVoir): Exquisitely crafted platinum jewellery is truly a red carpet favorite at Cannes this year. At the opening ceremony of the 70th ...
PanARMENIAN.Net - Julia Roberts will be returning to the big screen in Crystal City Entertainment's adaptation of "The Bookseller". It was announced Thursday, May ...
New Delhi [India], Mar.20 (ANI): Riding high on success with 'Quantico,' Priyanka Chopra is all smiles with all the love she has got in the West. Now that Season ...
New Delhi [India], Feb. 27: We all are aware of the big mess up of the 89th Academy Awards night- 'La La Land' was announced the 'Best Film' by mistake, instead ...
BERLIN: PanARMENIAN - Ildiko Enyedi's idiosyncratic love story On Body and Soul collected a trio of separate honors for the independent juries of the Berlin Film Festival, ...
New Delhi [India], Jan. 4 (ANI): The Bollywood film fraternity has slammed Samajwadi Party leader Abu Azmi for his sexist comment on Bengaluru mass molestation case. ...
New Delhi [India], Dec 26 (ANI): 'Thugs of Hindostan' already generated immense buzz on its announcement with a stellar cast of Aamir Khan and Amitabh Bachchan and the ...
CHENNAI, India - Thousands of supporters bid an emotional farewell to Indian politician Jayalalithaa, the "Amma" of millions, on Tuesday, who died late Monday night ...
TOKYO, Japan - Japan's Emperor Akihito made a rare televised appearance and addressed the public expressing his desire to “abdicate his ...
Leonardo DiCaprio has finally won his first Oscar for survival epic The Revenant, after six nominations, BBC reported.> Trend He was named best actor at the 88th Academy ...
Obama makes history on Twitter
Lowest ratings, lack of trust sum up Trump’s first 200 days
Trumpâ€™s working vacation watched curiously by Americans
Trump’s popularity hits rock bottom, even among white voters
Trump declares thereâ€™s no space for transgender people in military
Former FLOTUS Michelle Obama claims â€™racism hurt the mostâ€™
Trump, Sessions headed for an all out war? President publicly humiliates his Attorney General
Authorities fear more violence in Venezuela as opposition calls for 48-hour strike
U.S. Republicans divided after second healthcare bill collapses
Paris protesters decide to snub the American President, create ‘No Trump zone’ ahead of Bastille Day event
Brazils former president Lula sentenced to prison on graft and money-laundering charges
Donald Trump insists he did not collude with the Russians, but his son is singing a different tune - Why this matters
Two days before Independence Day, protesters for and against the American President, gathered in dozens of cities to voice concerns
Forget ethics and laws - America is appalled by the inappropriateness of Trumpâ€™s Twitter tantrums
How Trump sold a lie for years: The phoney Time magazine saga exposes a harsh truth about the American President
Google could face Europe-wide civil actions following multi-billion dollar ruling
An anxious Xi shall watch closely with the rest of Asia as Modi meets The Donald
How Donald Trump became richer by tens of millions of dollars as the President of America